

MARKET REPORT



Acne Vulgaris - Epidemiology Forecast to 2026

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acne Vulgaris - Epidemiology Forecast to 2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acne Vulgaris - Epidemiology Forecast to 2026

Acne Vulgaris - Epidemiology Forecast to 2026

Summary

Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is a common skin disease that predominantly affects adolescents and young adults, but can also persist into adulthood. Mortality is not associated with acne, although major physical and psychological characteristics may develop, such as acne scarring, poor self-esteem, depression, and anxiety. The distribution of acne in the population is influenced by genetic background and dietary habits.

For age- and sex-specific total prevalent cases, GlobalData epidemiologists utilized country-specific data from peer-reviewed journal articles, and for age-and sex-specific diagnosed prevalent cases and diagnosed prevalent cases by severity, GlobalData epidemiologists utilized a combination of primary research and data obtained from peer-reviewed journal articles. GlobalData epidemiologists forecast that the total prevalent cases of acne vulgaris in the 7MM will decrease by an Annual Growth Rate (AGR) of negative 0.13% per year over the next 10 years, from 157,919,985 cases in 2016 to 155,935,706 cases in 2026. GlobalData epidemiologists forecast that the diagnosed prevalent cases of acne vulgaris in the 7MM will decrease by an AGR of negative 0.13% per year over the next 10 years, from 78,960,002 cases in 2016 to 77,967,862 cases in 2026. In the 7MM, the US had the highest number of diagnosed prevalent cases with 32,308,734 in 2016, while Spain had the lowest number of diagnosed prevalent cases with 5,766,457 in 2016.

Scope

- The Acne Vulgaris report provides an overview of the risk factors and global trends for acne vulgaris in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of acne vulgaris segmented by sex and age (7-9 years, 10-17 years, and 18-60 years). Diagnosed prevalent cases of acne vulgaris are further segmented by severity (mild, moderate, severe) in both children and adolescents (7-17 years) and adults (18-60 years).
- The acne vulgaris epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Acne Vulgaris Epidemiology report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global acne vulgaris market.
- Quantify patient populations in the global acne vulgaris market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne vulgaris therapeutics in each of the markets covered.

- Understand magnitude of acne vulgaris population by disease severity.

Additional Details

Publisher : Global Data

Reference : GDHCER179-18

Number of Pages : 37

Report Format : PDF

Publisher Information :



GlobalData»

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Acne Vulgaris - Epidemiology Forecast to 2026 [Report Updated: 01-03-2018]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 31.2 List of Figures 32 Acne Vulgaris: Executive Summary 42.1 Related Reports 62.2 Upcoming Reports 73 Epidemiology 83.1 Disease Background 83.2 Risk Factors and Comorbidities 83.3 Global and Historical Trends 93.3.1 US 113.3.2 5EU 113.3.3 Japan 123.4 Forecast Methodology 133.4.1 Sources 133.4.2 Forecast Assumptions and Methods 163.5 Epidemiological Forecast for Acne Vulgaris (2016-2026) 213.5.1 Total Prevalent Cases of Acne Vulgaris 213.5.2 Diagnosed Prevalent Cases of Acne Vulgaris 223.5.3 Age-Specific Diagnosed Prevalent Cases of Acne Vulgaris 233.5.4 Sex-Specific Diagnosed Prevalent Cases of Acne Vulgaris 243.5.5 Diagnosed Prevalent Cases of Acne Vulgaris by Severity 253.6 Discussion 273.6.1 Epidemiological Forecast Insight 273.6.2 Limitations of Analysis 273.6.3 Strengths of Analysis 284 Appendix 294.1 Bibliography 294.2 Primary Research - KOLs Interviewed for this Report 314.3 Primary Research - Prescriber Survey 334.4 About the Authors 344.4.1 Epidemiologist 344.4.2 Reviewers 344.4.3 Global Director of Therapy Analysis and Epidemiology 354.4.4 Global Head and EVP of Healthcare Operations and Strategy 364.5 About GlobalData 374.6 Contact Us 374.7 Disclaimer 37

List Of Tables in Acne Vulgaris - Epidemiology Forecast to 2026 [Report Updated: 01-03-2018]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Diagnosed Prevalent Cases of Acne Vulgaris 9

Table 2: 7MM, Total Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, Both Sexes, N, Select Years 2016-2026 22

Table 3: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, Both Sexes, N, Select Years 2016-2026 23

Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 34

List Of Figures, Charts and Diagrams in Acne Vulgaris - Epidemiology Forecast to 2026 [Report Updated: 01-0-2018]

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of Acne Vulgaris, Both Sexes, Ages 7-60 Years, 2016 and 2026 5

Figure 2: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Both Sexes, Ages 7-60 Years, 2016 and 2026 6

Figure 3: Age-Standardized Total Prevalence of Acne Vulgaris, Ages 7-60 Years, 2016 10

Figure 4: Age-Standardized Diagnosed Prevalence of Acne Vulgaris, Ages 7-60 Years, 2016 11

Figure 5: Sources Used and Not Used to Forecast Total Prevalent Cases of Acne Vulgaris 14

Figure 6: Sources Used to Forecast Diagnosed Prevalent Cases of Acne Vulgaris 15

Figure 7: Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of Acne Vulgaris by Severity 16

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of Acne Vulgaris, Both Sexes, 2016 24

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, 2016 25

Figure 10: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-17 Years, Both Sexes, N, 2016 26

Figure 11: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 18-60 Years, Both Sexes, 2016 26

How to Buy...

Acne Vulgaris - Epidemiology Forecast to 2026 [Report Updated: 01-03-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/206717>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.